Compare GSK plc (GSK) vs Trade Desk Inc (TTD) Price & Performance

GSK plcTrade

Trade Desk IncTrade

Price performance (Past 24H)

Key statistics

GSK plc vs Trade Desk Inc — how do they compare? GSK plc trades at $52.65 (market cap $101.34B), while Trade Desk Inc trades at $19.22 (market cap $9.11B). The key difference: GSK plc is far larger — about 11.1× Trade Desk Inc's market cap, and GSK plc pays a 3.49% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals.

	GSK	TTD
Market Cap	$101.34B	$9.11B
Sector	Health	Technology
52-Week High	$61.18	$89.76
52-Week Low	$36.20	$17.33
Enterprise Value	$121.95B	$8.12B
Dividend Yield	3.49%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GSK plc

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Trade Desk Inc

TTD trades at $19.12, up 0.95% on the day, with a neutral technical signal and bearish moving averages. The company reported $2.9B revenue in 2025 with a net income margin of 15.3%, though Q1 2026 EPS missed expectations. Recent news includes executive appointments and expansion in Japan, while sentiment is mixed amid slowing growth concerns.

Outlook: TTD offers value at 22x P/E with strong profitability, but faces competitive pressure and growth deceleration. Analyst consensus is mixed with a $25.23 price target. Key risks include market share loss to larger rivals and execution on new initiatives.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GSK

UBS keeps GSK neutral, eyes CEO's strategy update over Q2 results and pipeline plansProactive Investors - Finance · 3 days agoNeutral UBS keeps GSK neutral, eyes CEO's strategy update and pipeline reprioritization after Nuvalent dealProactive Investors · 3 days agoNeutral View details →

TTD

The Trade Desk downgraded to Hold as growth slows and expenses rise despite low valuation.Seeking Alpha · 2 days agoBearish The Trade Desk stock falls 62% but remains a strong buy at 11x forward P/E with solid growth prospects.Seeking Alpha · 2 days agoBullish The Trade Desk integrates 7-Eleven Japan purchase data for precise ad targeting across digital channels.PRNewsWire · 2 days agoBullish View details →

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

About Trade Desk Inc

The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.